A blockbuster year of advancements in psychedelic-assisted therapies is culminating with recognition of the profound potential of emerging treatments for difficult-to-treat mental health conditions. On …
Psyche Unbound: Essays in Honor of Stanislav Grof is an extraordinary compilation of twenty-two essays that honor the path-breaking lifework of Stanislav Grof, M.D., Ph.D., the world’s leading researcher …
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …
MAPS is honored to announce the election of Carl L. Hart, Ph.D., to MAPS’ Board of Directors, effective as of October 22, 2021. to MAPS’ Board of Directors, effective as of October 22, 2021. Dr. Carl …
MAPS and its wholly owned drug-development subsidiary MAPS Public Benefit Corporation (MAPS PBC) have entered into a Memorandum of Understanding with Wesana Health Inc, a publicly traded, data-driven life …
MAPS) has been awarded a $12,979,050 grant from Michigan’s $20 million competitive 2021 Veteran Marijuana Research Grant Program. The program, which is funded by adult-use marijuana retail taxes, is …
The bill directs National Institute of Health (NIH) agencies to undertake and fund research into psychedelic-assisted therapies and potential benefits of cannabis, could accelerate the pace of research. …
Fifty years after the War on Drugs was officially declared and psychedelic substance prohibition began in contravention of evidence supporting therapeutic use, the California State Senate has taken the …
FOR IMMEDIATE RELEASEJune 7, 2021 California Senate Bill 519 decriminalizes the personal use and possession of psychedelic substances SB 519 will establish a task force to recommend regulatory systems …
Synergetic Press and the Multidisciplinary Association for Psychedelic Science (MAPS) are pleased to announce they have entered into a copublishing relationship effective May 1, 2021 which will greatly …
Phase 1 clinical trials of MDMA-assisted therapy for healthcare providers will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering …
